Sun Pharma (the Netherlands, owned by India’s Sun Pharmaceutical Industries Ltd.) has commissioned a production line for making solid peroral tablets with an annual capacity of 2 billion tablets at the Penza-based company Biosintez.
The company is working to fulfill one of the most important social tasks of making quality and affordable drugs for our citizens, First Deputy Minister for Industry and Trade Sergei Tsyb said at the dedication ceremony.
Sun Pharma increased its stake in PJSC Biosintez to 96.96% in 2019. More than 2% of Biosintez shares belong to Heumann Pharma GmbH & Co. Generica (Germany) whose end founder is India’s Torrent Private Ltd.
Businessman Boris Shpigel’s structures were the key owners of Biosintez before 2017.
Biosintez’s revenue amounted to 2.085 billion rubles in 2018, down 15.5% versus 2017. The company sustained 454.6 million rubles in losses in 2018 compared to 15.8 million rubles in net income a year earlier.